Dupilumab Demonstrates Rapid Onset of Response Across Three Type 2 Inflammatory Diseases

Dupilumab Demonstrates Rapid Onset of Response Across Three Type 2 Inflammatory Diseases

Type 2 inflammatory diseases often coexist in patients. Dupilumab targets type 2 inflammation and has demonstrated treatment benefits in patients with atopic dermatitis (AD), asthma, and chronic rhinosinusitis with nasal polyps (CRSwNP) with an acceptable safety profile.This post hoc analysis across...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Giorgio Walter Canonica, Arnaud Bourdin, Anju T. Peters, Martin Desrosiers, Claus Bachert, Stephan Weidinger, Eric L. Simpson, Nadia Daizadeh, Zhen Chen, Siddhesh Kamat, Asif Khan, Jingdong Chao, Neil M.H. Graham, Elizabeth Laws, Ana B. Rossi, Marius Ardeleanu, Leda Mannent, Nikhil Amin, Benjamin Ortiz, Yamo Deniz, Michel Djandji, Paul J. Rowe
Fformat: Artigo
Iaith:Saesneg
Cyhoeddwyd: 2022
Mynediad Ar-lein:https://doi.org/10.1016/j.jaip.2022.02.026
http://www.jaci-inpractice.org/article/S2213219822002276/pdf
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Rhyngrwyd

https://doi.org/10.1016/j.jaip.2022.02.026
http://www.jaci-inpractice.org/article/S2213219822002276/pdf

Eitemau Tebyg